Angion

About:

Angion Biomedica is a clinical stage organ restoration biopharmaceutical company focused on renal disease.

Top Investors: National Science Foundation, U.S. Department of Defense, Formic Ventures, Vifor Pharma

Description:

Angion Biomedica is a clinical-stage organ restoration biopharmaceutical company focused on renal disease. Its investigational drug BB3 is entering phase 3 for delayed graft function following kidney transplant and phase 2 for acute kidney injury following open-heart surgery using cardiopulmonary bypass.

Total Funding Amount:

$84.3M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Uniondale, New York, United States

Founded Date:

1998-01-01

Contact Email:

mail(AT)angion.com

Founders:

Itzhak Goldberg

Number of Employees:

101-250

Last Funding Date:

2021-02-05

IPO Status:

Delisted

Industries: